Heron Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on developing and commercializing therapeutic innovations that improve medical care. The company's product portfolio is structured into two primary commercial franchises: the Acute Care franchise, which includes ZYNRELEF (an extended-release dual-acting local anesthetic for postsurgical analgesia) and APONVIE (an intravenous formulation for the prevention of postoperative nausea and vomiting); and the Oncology Supportive Care franchise, which includes CINVANTI (an intravenous formulation of aprepitant) and SUSTOL (an extended-release injection of granisetron). Heron's proprietary Biochronomer drug delivery technology enables the sustained release of therapeutic levels of active pharmacological agents over several days to weeks.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Expansion of the commercial alignment program for ZYNRELEF throughout 2026, following a 111% growth in target accounts under the initial IGNITE program by year-end 2025.
Expected impact: Aims to expand target accounts by 40% and drive deeper hospital adoption and repeat account usage.
A commercial initiative focused on returning CINVANTI to steady growth by securing new formulary wins.
Expected impact: Targeting an increase of approximately $10 million in net revenue on an annual basis from potential new pipeline opportunities.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Crosslink serves as the lead partner in the U.S. for ZYNRELEF promotion for orthopedic indications, adding approximately 650 representatives to expand the sales network.
Terms: Five-year co-promotion agreement entered in January 2024.
Patheon manufactures and supplies specific quantities of products for Heron, conducts ongoing stability studies, and provides warehousing services.
Terms: Under the Framework Agreement signed in December 2025, Heron committed to purchase 38,400 kilograms of products through December 31, 2026.